PHS
PCRX icon

PFM Health Sciences’s Pacira BioSciences PCRX Stock Holding History

PFM Health Sciences’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-60,000
Closed -$3.15M – 92
2020
Q2 		$3.15M Buy
+60,000
New +$2.51M 0.16% 72

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

PFM Health Sciences's PCRX Position: Q3 2019 in Review

PFM Health Sciences sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 734,346 shares — an estimated $31.9M sold.

PFM Health Sciences first reported a position in PCRX in Q4 2016 and held it in 9 quarters. The position peaked at $138M in Q3 2018. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

  • PFM Health Sciences reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
  • PFM Health Sciences sold 734,346 Pacira BioSciences shares in Q3 2019, an estimated $31.9M.
  • PFM Health Sciences first reported a position in Pacira BioSciences in Q4 2016 and held it in 9 quarters.
  • PFM Health Sciences's Pacira BioSciences position peaked at $138M in Q3 2018.
  • 211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on PFM Health Sciences's 13F filing for Q3 2019, filed 14 Nov 2019.